Protocols
conversion
cyclosporin A
CsA
sirolimus
SRL
immunotherapy
transplantation
prevent
CsA-induced nephropathy
molecular mechanisms
protocols
nuclear
study
molecular pathways
putative
biomarkers
CsA-to-SRL
conversion
rat
model
animal groups
tested
weeks
control
CsA
SRL
conversion
CsA
weeks
SRL
weeks
serum
urinary
kidney tissue
gene
protein expression
markers
assessed
Renal lesions
analyzed
hematoxylin and eosin
periodic acid-Schiff
Masson's trichrome stains
SRL-treated
rats
proteinuria
NGAL
serum
urinary
markers
renal impairment
Short
CsA
treatment
absent
kidney
TGF-β
NF- κβ
mTOR
PCNA
TP53
KIM-1
CTGF
gene
protein changes
Prolonged
CsA
exposure
aggravated
renal damage
traditional
markers
serums
TGF- β
IL-7
TBARs
clearance
kidney
TGF-β
mTOR
SRL
CsA-induced renal damage evolution
absent/mild grade
NGAL
serum
urine
biomarker
CsA
replacement
SRL
